semaj83/ctmatch_classification huggingface dataset:
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 12.0-17.0,  Pain Males and females, aged 12 to 17 years, with pain severe enough to require daily, around-the-clock opioid treatment at a dose equivalent to at least 20 mg daily of hydrocodone for at least 2 weeks. 2. Patients must have stable vital signs and hemoglobin oxygen saturation, eg, measured by pulse oximetry (SpO2). 3. Patients must be willing and able to swallow medicinal tablets. 4. Female patients of childbearing potential must have a negative pregnancy test within 24 hours prior to the start of study drug treatment. 5. Female patients who are sexually active must be using (and continue using throughout the study) an acceptable method of birth control, per investigator's discretion. 6. Patients and patient's parent/caregiver must be compliant with the protocol, ie, must be able to perform study assessments and understand and complete the age-appropriate scale to rate pain intensity. 7. Patients must not have a cognitive developmental delay or any other condition that would preclude them from completing the age-appropriate pain scale  Patients who require a starting total daily dose of HYD > 120 mg. 2. Patients who have had surgery within 72 hours prior to the start of study drug treatment. 3. Patients who have any planned surgery during the study will be excluded. 4. Female patients who are pregnant or lactating. 5. Patients who are allergic to hydrocodone or any other component of HYD or have a history of allergies to other opioids. 6. Patients who receive or are expected to receive an investigational drug/therapy during the study drug treatment or follow-up period. 7. Patients who are anticipated to receive any hydrocodone or hydromorphone-containing products (other than study drug) during the study or 3 days prior to initiation of treatment with study drug. 8. Patients with a history of alcohol, medication, or illicit drug abuse or addiction and/or opioid abuse or addiction at any time. 9. Patients with contraindication to blood sampling. Other protocol-specific inclusion/
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 8.0-999.0,  Cystic Fibrosis Patient diagnosed with cystic fibrosis Girl aged 8 years of age, adolescents and young adults, had period or not visit the Reference and Competence Center of Cystic Fibrosis Affiliated to a social security scheme  Lack of consent of the legal representative or the relevant patient Patient majoring in legal disability or minor patient whose legal representative is legal disability
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Acute Scapholunate Injury Subjects willing and able to comprehend and sign Informed Consent Subjects who have received the SLIC screw as part of the treatment for scapholunate ligament repair or scapholunate reduction Subjects with acute scapholunate injury, classified with Garcia-Elias Stage 1-4, OR Geissler Stage 1-3 Subjects >18 years of age at the time of surgery  Subject diagnosed with chronic scapholunate injury Subjects who underwent previous scapholunate procedure on the study wrist before implantation of the SLIC Screw System Subjects with active or latent infection at the time of surgery Subjects with sepsis at the time of surgery Subjects diagnosed with osteoporosis at the time of surgery Subjects with insufficient quantity and/or quality of bone Subjects with cartilage degeneration on the bones at the time of surgery Subjects with absence of potential for soft tissue healing at time of surgery, as documented by the investigator Female Subjects known to be pregnant Subjects who were unable to follow postoperative care instructions, specifically, activity levels
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypereosinophilic Syndrome Patient having one of the three following hypereosinophilia> 1500 / mm3, checked on at least two samples (interval between 2 samples at the discretion of the clinician) or hypereosinophilia> 500 cells / mm3 and organ damage with infiltration NCB proven by pathological examination or hypereosinophilia> 500 cells / mm3 and found consistently for at least six months (present on all controls carried out before inclusion). 2. Patient affiliated or beneficiary of a social security system 3. Patient who signed the informed consent  Patient with solid tumors known (under chemotherapy or planned) 2. Patient unable to understand or to adhere to the Protocol 3. Patient unable to give consent 4. Pregnant or breastfeeding women 5. Patient already participating in an interventional trial
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 8.0-14.0,  Obesity Puberty Normal Physiology Girls without a chronic medical condition Normal weight (BMI 5th-85th%) or overweight/obese (BMI > 85th%) 14 years old Some breast development Pre-menarchal  Treated with medications that may affect reproductive hormones (e.g. birth control pills) Pregnancy During the study, the PI s discretion may be used to determine final eligibility. The PI s discretion may be used at any point in the study (pre-screening, clinical/lab assessments, etc.) to ensure participants are not subjected to unnecessary procedures or visits
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.0-14.0,  Fertility Preservation Lymphoma Pediatrics Cancer Gonadotropin-releasing Hormone Agonist Patients from 3 to 14 year old included Belong to one of these 3 groups (modified from Wallace et al, 2005) High risk : Conditioning therapy for bone marrow transplantation or pelvic irradiation Moderate/Low risk : Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML, osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL, Wilms tumour, retinoblastoma No risk (control group) : patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment  CNS (central nervous system) irradiation, cerebral tumour Current or previous ovarian disease/surgery Familial history of premature ovarian failure (no iatrogenic or surgical origins) Previous known severe chronic disease potentially affecting normal growth or puberty (diseases inducing malnutrition, anorexia, genetic/congenital disorders as Turner, Kallman, BPES(Blepharophimosis, ptosis, and epicanthus inversus syndrome) syndromes, uncontrolled severe diabetes, Cushing Syndrome, auto-immune diseases, cystic fibrosis, severe renal dysfunction) Genetic/congenital disorders inducing mental retardation
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 1.0-18.0,  Constitutional Tall Stature tall stature (height > 2 SD)  none
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-20.0,  Developmental Disabilities Children with aged 0-20 years 2. Control group: Children with orthopedic disease, Experimental group: Children with Developmental disabilities  Low cooperative with follow-up 2. Low cooperative with clinical assessment 3. Low cooperative with questionnaire writing and data collection
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Atrophic Vaginitis Menopause Menopausal with absence of menstruation for at least 12 months Presence of vaginal atrophy symptoms [subjective assessment of vaginal dryness >7cm on VAS) Prolapse stage < II, according to the pelvic organ prolapse quantification (POP-Q) system[31] No pelvic surgery within 6 months prior to treatment (vulva biopsy may be included after 2 weeks) Understanding and acceptance of the obligation to return for all scheduled follow-up visits  Personal history of vulvovaginal condyloma,,vaginal intraepithelial neoplasia (VAIN), vaginal carcinoma, lichen sclerosis, lichen planus, history of vaginal radiation, history of cervical cancer, other gynecologic cancer, or pelvic radiation Acute or recurrent urinary tract infection (UTI), or genital infection (e.g. bacterial; vaginosis, herpes genitalis, candida) Personal history of Scleroderma Any serious disease, or chronic condition, that could interfere with the study compliance Previously undergone reconstructive pelvic surgery within the past 6 months Previously undergone reconstructive pelvic surgery with transvaginal mesh kits and sacrocolpopexy with synthetic mesh for prolapse, excluding synthetic slings (unless current untreated exposure or extrusion) Have used vaginal estrogen cream, ring or tablet within 1 month prior to entering the study Vaginal moisturizers, lubricants or homeopathic preparations within 2 weeks of therapy Personal history of thrombophlebitis Personal history of heart failure or myocardial infarction within 12 months of procedure
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 6.0-16.0,  Noonan Syndrome Genetically confirmed Noonan syndrome Female child between 6 to 15 years, without menses, with bone age < 13 years Male child between 6 to 16 years, with bone age < 14 years Decreased growth velocity (< -1 SDS) and/or short stature (height < -2 SDS or -1,5 SDS under target height) Informed consent obtained from child and parents  Contraindication to simvastatin treatment  Progressive liver disease, increased serum levels of alanine aminotransferase (ALT) (> 1,5 uper limit of normal (ULN)), aspartate aminotransferase (> 1,5 ULN) Known hypersensitivity to simvastatin Pregnancy Treatment with CYP3A4 inhibitors (erythromycin, clarithromycin, ketoconazole, or itraconazole) Growth promoting therapies such as recombinant human Growth Hormone (GH) or IGF-1 treatment
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 4.0-999.0,  Inherited Eye Disease To be eligible, the following must be met, where applicable; 1. Participant must be four years of age or older. 2. Participant must understand and sign the protocol s informed consent document. 3. Individuals or family members of individuals with inherited eye diseases, either congenital, childhood, or age related. 4. All participants must be able to cooperate with study examination and phlebotomy  A participant is not eligible if any of the following are present: 1. Participant has a disease, infection, or trauma that mimic inherited cataracts, retinal degenerations, glaucoma, etc. 2. Participant has a significant active infection (an infection requiring treatment as determined by the investigator) or a history of chronic or recurrent infections. 3. Participant requires sedation for study procedures
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 2.0-12.0,  Neurodevelopmental Disorders Developmental Disabilities Children aged between 2-12 years Screen positive on any of the Ten Questions screen questionnaire items # 1,4,5,7,8,9,10 for developmental disorders and delays Developmental disorder and delay present according to clinical assessment (History & clinical examination for developmental delay in motor, communication, social, cognitive, daily living skills domains according to mhGAP developmental disorders guidelines for clinical assessment  Co-morbid physical or mental conditions in the child requiring inpatient hospitalization Deafness or blindness in the child Primary caregiver not available or unwilling to participate in the intervention program for 6 months Physical or mental conditions in the primary caregiver needing inpatient hospitalization or frequent outpatient visits (more than two times a month) Written consent not obtained for participation in the trial by the primary caregiver
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.5-18.0,  Celiac Disease Child with clinical suspicion of CD (chronic or recurrent diarrhea, Failure to thrive, growth impairment , iron deficiency anemia, vomiting, chronic abdominal pain, abdominal distension , constipation, fatigue, recurrent oral aphthous or dermatitis herpetiformis) and high TG2 serology (>2 times upper limit of normal) who is referred to gastroscopy and intestinal biopsies Or 2. Asymptomatic child who belongs to high risk group of celiac (Diabetes mellitus type 1, Hashimoto thyroiditis, Down syndrome, Turner syndrome, Williams syndrome, Auto-immune Hepatitis or first degree with CD) and high TG2 serology (>2 times upper limit of normal) who is referred to gastroscopy and intestinal biopsies . and 3. signed consent form  IgA (Immunoglobulin A) deficiency 2. Malignancy 3. Inflammatory Bowel Disease 4. Severe chronic infection (HIV, Tuberculosis) 5. Primary immunodeficiency
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cancer of the Endometrium Having a pathological diagnosis of hyperplasia or endometrial cancer consent to participation in the study  Not affiliated to a social security scheme
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 6.0-18.0,  Diabetes Mellitus, Type 1 Children and teenagers from 6 years-old to 18 years-old Having diabetes treated by insulin for at least 1 year Followed in pediatric diabetology department of Arnaud de Villeneuve Hospital in University Hospital of Montpellier Study Inform Consent signed by both children and parents  Children with developmental delay, severe mental disorders or language delay Non French-speaking family Children who does not live with at least one of his/her parents Children whose residence is not compatible with frequent visits at University Hospital of Montpellier Clinical status not compatible with study questionnaires assessment
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 6.0-17.0,  Cerebral Palsy Cerebral palsy hemiplegic diplegic or tetraplegic spastic or not Children who feel pain during the pre-screening physiotherapy session with a VAS score above 2 Aged 6 to 17 years of both gender Ability to express his/her pain and to measure its intensity with VAS Informed and signed (parents, investigator and child if possible)  Lack of physiotherapy Analgesic treatment already available or stopped in the last month Scheduled surgery procedure or botulinum toxin injection during the period of the assessment of pain (around 5 month) The last botulinum toxin injection in two months before the Child who feel pain with EVA score superior or equal to 4 at the time of the outside the sessions of physiotherapy Child unable to cooperate Severe infection or instable vital functions Hypersensitivity to ibuprofen or any of the constituents in the product History of allergy or asthma triggered by taking ibuprofen or substances of near activity such as other NSAIDs and aspirin Allergy to other component of treatment